0.78
Schlusskurs vom Vortag:
$0.7634
Offen:
$0.78
24-Stunden-Volumen:
1.05M
Relative Volume:
0.42
Marktkapitalisierung:
$126.22M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
19.50
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
+13.54%
1M Leistung:
+11.17%
6M Leistung:
-79.03%
1J Leistung:
-88.60%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IRWD
Ironwood Pharmaceuticals Inc
|
0.78 | 111.17M | 400.57M | 9.21M | 146.36M | 0.04 |
![]()
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
2024-01-17 | Eingeleitet | Craig Hallum | Buy |
2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
2023-11-09 | Eingeleitet | Jefferies | Buy |
2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
2022-09-02 | Eingeleitet | CapitalOne | Overweight |
2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-06-17 | Eingeleitet | Northland Capital | Outperform |
2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
2017-04-07 | Bestätigt | Mizuho | Buy |
2017-02-22 | Bestätigt | Barclays | Equal Weight |
2016-11-04 | Bestätigt | Mizuho | Buy |
2016-10-24 | Bestätigt | Wedbush | Neutral |
2016-10-10 | Bestätigt | Mizuho | Buy |
2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
What drives Ironwood Pharmaceuticals Inc. stock priceOutperformance with explosive growth - jammulinksnews.com
Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
Is Ironwood Pharmaceuticals Inc. a good long term investmentOutstanding capital growth - jammulinksnews.com
What analysts say about Ironwood Pharmaceuticals Inc. stockExceptional stock performance - PrintWeekIndia
How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com
How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyFast Moving Stock Alerts - Newser
Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - The Globe and Mail
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - MenaFN
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY - Investing.com
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc.(NasdaqGS: IRWD) added to Russell 3000E Index - MarketScreener
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st
Ironwood Pharma Elects Directors at Annual Meeting - TipRanks
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Is A Good Stock To Invest In - Stocksregister
Ameriprise Financial Inc. Trims Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer - GlobeNewswire
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock By Investing.com - Investing.com India
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock - Investing.com Australia
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - MSN
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call - MSN
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $4.78 - Defense World
Pacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Pacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):